Jubilant Pharmova Share Price
18 Nov, 2026 3:21 PM (IST)
Jubilant Pharmova Performance
- Today's Low
- ₹932
- Today's High
- ₹954
- 52 Week Low
- ₹786
- 52 Week High
- ₹1,161
- Open Price₹950
- Previous Close₹955
- Volume130,602
- 50 DMA₹959.80
- 100 DMA₹960.40
- 200 DMA₹967.80
Jubilant Pharmova Chart
Investment Returns
- Over 1 Month -0.79%
- Over 3 Month + 7.41%
- Over 6 Month -5.96%
- Over 1 Year -19.65%
Smart Investing Starts Here Start SIP with Jubilant Pharmova for Steady Growth!
Jubilant Pharmova Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 56.4
- PEG Ratio
- -1.3
- Market Cap Cr
- 14,832
- P/B Ratio
- 2.1
- Average True Range
- 32.6
- EPS
- 16.5
- Dividend Yield
- 0.5
- MACD Signal
- 0.5
- RSI
- 48.85
- MFI
- 42.02
Latest Stock News Updates
Investor Meet Outcome
- BSE India
- 1 day 22 hours ago
<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Jubilant Pharmova announced Q2FY27 results</strong></span></h3> <p><strong>Consolidated Financial Highlights</strong>:</p> <ul> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Total Revenue from Operations:</strong> Stood at Rs 23,700 million in Q2FY27 (sales/income from operations of Rs 23,602 million and other operating income of Rs 98 million), increasing by 6.31% QoQ from Rs 22,294 million in Q1FY27 and by 20.52% YoY from Rs 19,664 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Other Income:</strong> Recorded at Rs 144 million in Q2FY27, declining by 27.64% QoQ from Rs 199 million in Q1FY27 and rising by 46.94% YoY from Rs 98 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Total Income:</strong> Reached Rs 23,844 million in Q2FY27, up 6.01% QoQ from Rs 22,493 million in Q1FY27 and up 20.66% YoY from Rs 19,762 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Profit Before Share of Loss of an Associate and Exceptional Items:</strong> Stood at Rs 617 million in Q2FY27, declining by 28.59% QoQ from Rs 864 million in Q1FY27 and by 68.55% YoY from Rs 1,962 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Profit Before Tax (PBT):</strong> Recorded at Rs 617 million in Q2FY27 (with nil share of loss of an associate and nil exceptional items), down 28.59% QoQ from Rs 864 million in Q1FY27 and down 67.58% YoY from Rs 1,903 million in Q2FY26 (which included an associate loss share of Rs 1 million and an exceptional item of Rs 58 million).</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Profit for the Period (PAT):</strong> Stood at Rs 310 million in Q2FY27, decreasing by 45.04% QoQ from Rs 564 million in Q1FY27 and by 74.15% YoY from Rs 1,199 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Profit Attributable to Owners of the Company:</strong> Recorded at Rs 312 million in Q2FY27 (with non-controlling interest at a loss of Rs 2 million), down 44.78% QoQ from Rs 565 million in Q1FY27 and down 74.06% YoY from Rs 1,203 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Total Comprehensive Income:</strong> Reached Rs 1,006 million in Q2FY27 (with Rs 1,008 million attributable to owners), surging by 169.71% QoQ from Rs 373 million in Q1FY27 and declining by 64.11% YoY from Rs 2,803 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Earnings Per Share (Face Value Re. 1 each):</strong> Basic EPS stood at Rs 1.97 in Q2FY27 (down 44.82% QoQ from Rs 3.57 in Q1FY27 and down 74.04% YoY from Rs 7.59 in Q2FY26), while Diluted EPS stood at Rs 1.96 in Q2FY27 (down 44.94% QoQ from Rs 3.56 in Q1FY27 and down 74.11% YoY from Rs 7.57 in Q2FY26).</li> </ul> <p><strong>Standalone Financial Highlights</strong>:</p> <ul> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Total Revenue from Operations (Continuing Operations):</strong> Stood at Rs 685 million in Q2FY27, increasing by 2.09% QoQ from Rs 671 million in Q1FY27 and by 3.16% YoY from Rs 664 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Other Income (Continuing Operations):</strong> Recorded at Rs 9 million in Q2FY27, up 800.00% QoQ from Rs 1 million in Q1FY27 and up 12.50% YoY from Rs 8 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Total Income (Continuing Operations):</strong> Reached Rs 694 million in Q2FY27, up 3.27% QoQ from Rs 672 million in Q1FY27 and up 3.27% YoY from Rs 672 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Profit Before Tax (Continuing Operations):</strong> Stood at Rs 103 million in Q2FY27 (with nil exceptional items across all three quarters), rising by 5.10% QoQ from Rs 98 million in Q1FY27 and by 21.18% YoY from Rs 85 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Profit / (Loss) for the Period from Continuing Operations:</strong> Recorded at Rs 76 million in Q2FY27, up 4.11% QoQ from Rs 73 million in Q1FY27 and turning profitable YoY compared with a loss of Rs 480 million in Q2FY26 (which included a deferred tax charge of Rs 551 million).</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Profit / (Loss) for the Period (Continuing & Discontinued Operations):</strong> Stood at Rs 76 million in Q2FY27 (discontinued operations were nil in Q2FY27 and Q1FY27), up 4.11% QoQ from Rs 73 million in Q1FY27 and turning profitable YoY compared with a net loss of Rs 64 million in Q2FY26 (which included profit after tax from discontinued operations of Rs 416 million).</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Total Comprehensive Income / (Loss):</strong> Reached Rs 77 million in Q2FY27, up 4.05% QoQ from Rs 74 million in Q1FY27 and turning positive YoY compared with a total comprehensive loss of Rs 72 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Earnings Per Share (Basic & Diluted, Face Value Re. 1 each):</strong> For continuing operations, EPS stood at Rs 0.48 in Q2FY27 (up 4.35% QoQ from Rs 0.46 in Q1FY27 vs Rs (3.02) in Q2FY26); for continuing and discontinued operations combined, EPS stood at Rs 0.48 in Q2FY27 (up 4.35% QoQ from Rs 0.46 in Q1FY27 vs Rs (0.40) in Q2FY26).</li> </ul> <p><strong>Business Highlights</strong></p> <ul> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Segment-wise Performance (Consolidated):</strong> <ul> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Radiopharma:</strong> Segment revenue stood at Rs 10,093 million in Q2FY27, down 1.25% QoQ from Rs 10,221 million in Q1FY27 and up 12.51% YoY from Rs 8,971 million in Q2FY26. Segment PBIT (before exceptional items) stood at Rs 698 million, declining by 10.51% QoQ from Rs 780 million in Q1FY27 and by 26.91% YoY from Rs 955 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Allergy Immunotherapy:</strong> Segment revenue stood at Rs 2,295 million in Q2FY27, up 7.04% QoQ from Rs 2,144 million in Q1FY27 and up 18.30% YoY from Rs 1,940 million in Q2FY26. Segment PBIT stood at Rs 657 million, increasing by 3.46% QoQ from Rs 635 million in Q1FY27 and decreasing by 12.28% YoY from Rs 749 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Contract Development and Manufacturing Organisation - Sterile Injectables:</strong> Segment revenue stood at Rs 5,596 million in Q2FY27, growing by 7.66% QoQ from Rs 5,198 million in Q1FY27 and by 35.99% YoY from Rs 4,115 million in Q2FY26. Segment PBIT turned to a loss of Rs 42 million in Q2FY27, compared with profits of Rs 73 million in Q1FY27 and Rs 710 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Contract Research, Development and Manufacturing Organisation:</strong> Segment revenue stood at Rs 3,448 million in Q2FY27, rising by 5.83% QoQ from Rs 3,258 million in Q1FY27 and by 10.34% YoY from Rs 3,125 million in Q2FY26. Segment PBIT stood at Rs 200 million, declining by 43.82% QoQ from Rs 356 million in Q1FY27 and by 31.03% YoY from Rs 290 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Generics:</strong> Segment revenue stood at Rs 2,741 million in Q2FY27, surging by 58.07% QoQ from Rs 1,734 million in Q1FY27 and by 64.13% YoY from Rs 1,670 million in Q2FY26. Segment PBIT turned profitable at Rs 51 million in Q2FY27, compared with losses of Rs 101 million in Q1FY27 and Rs 3 million in Q2FY26.</li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">Proprietary Novel Drugs:</strong> Segment revenue remained nil across all three quarters, while segment loss stood at Rs 102 million in Q2FY27, widening by 34.21% QoQ from a loss of Rs 76 million in Q1FY27 and by 251.72% YoY from a loss of Rs 29 million in Q2FY26.</li> </ul> </li> <li _ngcontent-ng-c4008426745=""><strong _ngcontent-ng-c4008426745="">NCD Issuance Subsequent to Q2FY27:</strong> Subsequent to Q2FY27 (in Q3FY27), the Board approved the issuance of up to 80,000 listed, rated, redeemable non-convertible debentures (NCDs) of face value Rs 1,00,000 each aggregating up to Rs 8,000 million on a private placement basis, and the Company subsequently allotted unsecured NCDs aggregating to Rs 8,000 million to successful bidders.</li> </ul> <p><strong>Shyam S Bhartia, Chairman, Jubilant Pharmova and Mr. Hari S Bhartia, Co-Chairman & Non-Executive Director, Jubilant Pharmova said,</strong> “We are pleased to announce revenue of Rs. 2,370 Cr. for Q2’FY27, which reflects a solid growth of 21% on YoY basis. Revenue growth is broad-based across all our business segments, but particularly strong in CDMO Sterile Injectables on the back of technology transfer revenues from the new and third line. EBITDA for the quarter stands at Rs. 255 Cr. EBITDA margins declined year-on-year, primarily due to the unavailability of high-margin SPECT radiopharmaceutical products in the Radiopharmaceuticals business. Additionally, margins were impacted by higher operating expenses, including incremental remediation costs at the CMO Montreal facility. Reported PAT for the period stands at Rs. 31 Cr. PAT margins decreased due to lower operating profitability and an increase in depreciation.</p> <p>During Q2’FY27, we saw continued growth momentum in the Ruby-Fill installs. We also saw the release of Commercial SPECT radiopharmaceutical product from CMO Montreal, post the restart of production. We signed an agreement with a large radiopharmaceutical player to distribute one of the leading PET diagnostic products through our new PET pharmacies. In the Allergy Immunotherapy business, we witnessed increase in demand from both markets, US and outside the US. In the CDMO Sterile Injectables business, we signed a master services agreement with a large innovator pharma company for manufacturing and commercial supply of one of the largest oncology products. In the CRDMO business, we expect increase in revenues from Biotech customer segment and custom manufacturing revenue line. In the Generics Business, we saw sharp revenue growth on the back of multiple new products launched in FY27. Lastly, in our Proprietary Novel drugs business, we presented initial clinical data from JBI-802 Phase 1/2 clinical trial, demonstrating rapid, sustained and durable, dose-dependent reductions in platelet counts with a manageable safety profile. We are also pleased to share that we have successfully raised Rs. 800 Cr. through Non-convertible debentures. The proceeds shall be utilised towards refinancing of debt and capex.”</p> <p><a class="lb" href="/get-document/post/pdf/5950329/" target="_blank">Result PDF</a></p>
- Trendlyne
- 2 days 2 hours ago
Newspaper Publication
- BSE India
- 3 days 16 hours ago
Jubilant Pharmova Financials
Jubilant Pharmova Technicals
EMA & SMA
- Bearish Moving Average 16
- Bullish Moving Average 0
- 20 Day
- ₹957.00
- 50 Day
- ₹959.80
- 100 Day
- ₹960.40
- 200 Day
- ₹967.80
Resistance and Support
- R3 1,024.40
- R2 1,005.70
- R1 980.10
- S1 935.80
- S2 917.10
- S3 891.50
Jubilant Pharmova Corporate Actions - Bonus, Splits, Dividends
About Jubilant Pharmova
Jubilant Pharmova engaged in six businesses, including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing of sterile injectables, Contract Research Development and Manufacturing, Generics and Proprietary Novel Drugs businesses. View More- NSE Symbol
- JUBLPHARMA
- BSE Symbol
- 530019
- ISIN
- INE700A01033
Similar Stocks to Jubilant Pharmova
Popular Stocks
Jubilant Pharmova FAQs
Jubilant Pharmova share price is ₹931 As on 18 November, 2026 | 15:06
The Market Cap of Jubilant Pharmova is ₹14831.5 Cr As on 18 November, 2026 | 15:06
The P/E ratio of Jubilant Pharmova is 56.4 As on 18 November, 2026 | 15:06
The PB ratio of Jubilant Pharmova is 2.1 As on 18 November, 2026 | 15:06
The 52 week High & Low of Jubilant Pharmova is ₹1160.8/₹786 respectively As on 18 November, 2026 | 15:06
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.